Comparison of clinical remission criteria for severe asthma patients receiving biologic therapy

Anna Breslavsky, Ahsen Al Qaied, Philip Tsenter, Nikita Mukaseev, Mohamed Alamor, Keren Cohen-Hagai, Ori Wand*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


Background: The concept of remission on biological treatment has been suggested as a therapeutic target for patients with severe asthma, composed of 1. no chronic use of systemic steroids, 2. no exacerbations, 3. minimal symptoms, and 4. optimized lung function, for a significant time. However, the criteria for remission are not clearly defined. Objective: Our objective was to compare different criteria for remission in subjects receiving biologicals for severe asthma. Methods: A cross-sectional study of adult subjects who receive a stable regimen of a biological for severe asthma for at least 6-months. We compared the proportion of subjects who fulfilled different specific criteria in the four domains, as well as those who achieved different composite outcome measures of clinical remission. Results: Of 39 subjects, 28 were females (71.8%), mean age 60.4. Twelve were current or past smokers (30.8%). Twelve had prior different biological treatment (30.8%), and 3/39 had more than one previous treatment (7.7%). Current biological included mepolizumab 12/39 (30.8%), dupilumab 11/39 (28.2%), benralizumab 10/39 (25.6%), omalizumab 5/39 (12.8%), reslizumab 1/39 (2.6%). Different specific criteria were achieved in 39–80% of subjects, being highest for no chronic steroid use and lowest for symptoms control and lung function. Overall remission was obtained by 20–41%, depending on definition, with significant variability in agreement between different sets of remission criteria (Cohen's kappa 0.33–0.89). Conclusion: Clinical remission is achievable in real-world severe asthmatics on biological therapies. The core criteria for remission should be better defined.

Original languageEnglish
Article number107528
JournalRespiratory Medicine
StatePublished - Feb 2024


  • Asthma
  • Benralizumab
  • Dupilumab
  • Mepolizumab
  • Omalizumab
  • Remission
  • Reslizumab


Dive into the research topics of 'Comparison of clinical remission criteria for severe asthma patients receiving biologic therapy'. Together they form a unique fingerprint.

Cite this